|
Match
|
Document |
Document Title |
|
|
6919374 |
Viscosity modulating substance and use thereof
It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patient, including those suffering from sickle cell disease and plasma cell...
|
|
|
6919315 |
Compounds with growth hormone releasing properties
Disclosed are compounds of formula I formula I
wherein R 1 , R 2 , R 5 , R 6 , R 7 , R 8 , G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing...
|
|
|
6913761 |
Bioimplant formulation
A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-foaming agent and the balance stearin....
|
|
|
6911431 |
Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R′-Glu-Trp-R″.
|
|
|
6903075 |
Heterocyclic amide compounds as cell adhesion inhibitors
Compounds of Formula I are antagonists of VLA-4 and/or α 4 β 7 , and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds...
|
|
|
6890905 |
Methods for improving islet signaling in diabetes mellitus and for its prevention
The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic...
|
|
|
6884782 |
STAT modulators
The present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and...
|
|
|
6875609 |
Methods for the early diagnosis of ovarian cancer
The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. Specifically,...
|
|
|
6867192 |
Compounds useful in the treatment of inflammatory diseases
There are provided according to the invention, novel compounds of formula (I)
wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification, processes for preparing them,...
|
|
|
6867202 |
Treatment of insulin resistance
This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I,
where the variables are defined in...
|
|
|
6858396 |
Positively charged non-natural amino acids, methods of making and using thereof in peptides
This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides.
|
|
|
6855695 |
Water-soluble SHPs as novel alkylating agents
The present invention relates to compounds according to the structure (I):
Where R is —CH 3 or —CH 2 CH 2 Cl; R′ is C 1 -C 7 alkyl or —CH 2 CH 2 Cl; R 2 or R 4 is OPO 3 H 2 , NO 2...
|
|
|
6849605 |
Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which...
|
|
|
6838475 |
Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus
The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
|
|
|
6838439 |
Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists
The present invention relates to compounds of the formula I
which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to...
|
|
|
6835714 |
Heterocyclic compounds, intermediates thereof and elastase inhibitors
The present invention relates to a heterocyclic compound of the following formula (I-a), its ester, or a salt thereof, and a human neutrophilic elastase inhibitor containing the same as the active...
|
|
|
6828302 |
Therapeutic uses of depsipeptides and congeners thereof
Depsipeptides and congeners thereof are disclosed having the following structure: wherein m, n, p, q, X, R 1 , R 2 and R 3 are as defined herein. These compounds including FR901228, have...
|
|
|
6818622 |
Selective MMP inhibitors having reduced side-effects
The subject invention pertains to matrix metalloproteinase (MMP) inhibitors that exhibit an IC 50 of below 10 −4 M against MMP and have substantially no activity against non-MMP...
|
|
|
6818662 |
Pharmaceutical composition
The present invention provides a pharmaceutical composition comprising N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformami
dine and sulfobutyl ether β-cyclodextrin or a salt thereof,...
|
|
|
6812222 |
Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
The present invention relates to a peritoneal dialysis solution comprising at least one amino sugar in an effective amount sufficient to create an osmotic pressure to effect the removal of water by...
|
|
|
6811996 |
DDS compounds and method for assaying the same
A drug delivery system compound comprising a carboxy(C 1-4 )alkyldextran polyalcohol modified with a saccharide compound and a residue of drug compound bound to the carboxy(C 1-4 )alkyldextran...
|
|
|
6806284 |
Photosensitizers with ligand targeting properties for tumor therapy
The present invention provides a drug delivery system wherein a “parachute” structure is coupled to a therapeutic compound. The “parachute” structure comprises hydrophilic branched...
|
|
|
6806256 |
Taste masked liquid pharmaceutical compositions
This invention is directed to a taste masked liquid pharmaceutical composition comprising a pharmaceutically active agent and a taste masking composition. In particular, the taste masking...
|
|
|
6803046 |
Sincalide formulations
The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention...
|
|
|
6800612 |
S-nitrosothiols as agents for the treatment of circulatory dysfunctions
The present invention is directed to a S-nitrosothiol derivative of penicillamine or glutathione, of formula I: or its pharmaceutically acceptable salt thereof, in which: A and B are...
|
|
|
6797700 |
Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
The present invention relates to peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated...
|
|
|
6794365 |
Malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them
The present invention relates to new malonic acid derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated in the claims. The compounds of formula...
|
|
|
6790834 |
Cytostatic agents
Compounds of formula I are disclosed wherein R 4 is an ester or thioester group, and R, R 1 , R 2 , and R 3 are as defined in the specification are inhibitors of rapidly dividing tumor cells.
|
|
|
6784158 |
Method for preparing a compound with growth hormone releasing properties
A method for preparing a compound of formula I or a salt thereof is disclosed.
|
|
|
6777403 |
Method and structure for inhibiting activity of serine elastases
Therefore, it is critical that the roles these enzymes play in biological processes outside of extracellular matrix degradation or remodeling be understood in order to assess their potential as...
|
|
|
6774110 |
Orally available peptidic thrombin inhibitors
The present invention relates to novel thrombin inhibitors that are useful as anticoagulants. More particularly, the present invention is directed to peptide derivatives having high antithrombotic...
|
|
|
6770627 |
Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p 53
A compound of formula (1), wherein: R 5 is hydrogen, C 1-4 alkyl, R 6 CH 2 — or R 6 C(O)—; R 6 is aryl, heteroaryl, heterocyclyl, aminoC 3-6 alkyl, N-(C 1-4 alkyl)aminoC 3-6 alkyl, NN-(diC...
|
|
|
6753316 |
Acryloyl derivatives analogous to distamycin, process for preparing them, and their use as antitumor agents
Compounds which are acryloyl substituted distamycin derivatives of formula (I) wherein: n is 2, 3 or 4; m is 1 or 2; X and Y are the same or different and are selected, independently for each...
|
|
|
6753317 |
Dmt-Tic di- and tri-peptide derivatives and related compositions and methods of use
A compound of formula: comprising the Dmt-Tic pharmacophore and related compositions and methods of use in the inhibition of the binding of an opioid receptor-binding compound with a...
|
|
|
6750209 |
Advanced glycation end-product intermediaries and post-amadori inhibition
The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation,...
|
|
|
6747009 |
Peptidomimetic glutathione analogs
The invention relates to peptidomimetic compounds with formula wherein Z═CH 2 and Y═CH 2 , or Z═O and Y═O═O, which are novel analogs of glutathion and are inhibitors of glutathione...
|
|
|
6746837 |
Multiple drug resistance gene atrD of aspergillus nidulans
The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus nidulans . Vectors and transformed host cells comprising the multiple drug...
|
|
|
6740657 |
Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
The invention is directed to novel aminomethyl-pyrroloquinazoline compounds and pharmaceutical compositions thereof which are useful thrombin receptor or PAR-1 antagonists, methods for production...
|
|
|
6737410 |
Inhibitors of protein farnesyl transferase
The present invention provides compounds having the structure represented by Formula I: and methods of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a...
|
|
|
6730660 |
Peritoneal dialysis solutions with polypeptides
The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such...
|
|
|
6716818 |
Caspase inhibitors and the use thereof
The present invention is directed to novel dipeptide thereof, represented by the general Formula I: where R 1 -R 3 , X and Y are defined herein. The present invention also relates to the...
|
|
|
6699835 |
Formulation of boronic acid compounds
The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds...
|
|
|
6693072 |
Elastase inhibitors
This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P 2 moiety is substituted...
|
|
|
6689754 |
Heterocyclic glycyl β-alanine derivatives
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and...
|
|
|
6689801 |
Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
Novel thiol derivatives of formula I or of the formula Ia wherein the variables have the meanings as defined hereinbefore.
|
|
|
6686335 |
Hydroxamate-containing cysteine and serine protease inhibitors
The present invention is directed to hydroxamate-containing inhibitors of cysteine and serine proteases. Methods for the use of the protease inhibitors are also described.
|
|
|
6686336 |
N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
The invention provides a compound of formula I: wherein R 1 -R 3 have any of the values described in the specification; or a salt thereof. The compounds are useful as aldehyde sequestration...
|
|
|
6683055 |
Low molecular weight inhibitors of complement proteases
Peptide substances, their preparation and their use as complement inhibitors are described. These are in particular substances having a guanidine or amidine radical as a terminal group. In...
|
|
|
6677308 |
Meta-substituted phenylene sulphonamide derivatives
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula...
|
|
|
6677376 |
Non-peptidic cyclophilin binding compounds and their use
The invention relates to non-peptidic compounds that possess bioactive properties, such as the ability to protect neuronal cells from otherwise lethal treatments or the ability to promote the...
|